TRIPLE POSITIVE GROUP
Comments
-
crystal deodorant Is what I use the radiation department said that was what to use.
0 -
I started making my own deodorant - mix equal amounts of baking soda and arrowroot powder. Add coconut oil and mix until a smooth paste. It really works.
0 -
I do the same, flaviarose, but without the arrowroot powder (just because I never bought it). It really does work!! I do yoga, run and lift weights and I sweat A LOT, but never smell bad!! It's been over two years since I made the switch. I even have my husband and one of my sons on board.
0 -
Tomboy, like Lago, mine should have been picked up at least 2 years earlier. If it had, would have only been DCIS & I would not have required 6 months of chemo & radio etc.
During my treatment I found 2 lumps in my remaining breast, I too was treated like the "girl who cried wolf". My oncologist & BS were extremely reluctant to order an MRI (the BC in my right breast was not picked up on mammo or U/S) so of course I was terrified.
You are definitely doing the right thing, hoping it will all come back ok for you.
0 -
One of the things I like about that site is that you can search for individual products you currently use to check them out, or you can put in whatever type of product you are interested in, like "mascara", and get the best to worst listing - this helps make choices easier.
0 -
For those of you making your own deoderant...how do you apply it? What kind of container do you store it in? This website was definitely an eye opener for me. My oldest DS had eczema when he was a baby. I used Aveeno body wash and cream lotions on his skin for the first couple years. After that he seemed to be ok. A little over a year ago we switched to Suave Men's body wash for him because he was pretty smelly after baseball. His body broke out in little hives. It took us a little while to finally figure out it was from the body wash. We went back to the Suave for kids. According to this website, it is rated high for allergies. I'm going to need to find something else for the kids to use now.
0 -
Hello all - I hope everyone had a great holiday season. I had my first mammo since DX yesterday. A little anxious. My surgeon said she would call with the results as soon as she had them. It was one year NED December 30th. YAY!Thank you for the link to the products. I changed shampoo, conditioner and lotion since diagnosis, but have not changed the deodorant or soap yet. Have any of you colored your hair since diagnosis?
Everyone have a great day!
0 -
I highlighted mine prior to dx, it grew back in very salt & pepper, heavy on the salt. I colored it light brown as soon as my hairdresser said it was long enough (any shorter and she said we would essentially be painting my head) and I highlighted it again as soon as it was long enough to foil. Some people opt for more natural haircolor products, but that is one area that I have not pursued.
Here is the EWG section on hair color:
http://www.ewg.org/skindeep/browse/hair+color+and+bleaching/
0 -
6 month mammo tomorrow. Will be in touch. Ugh! Need xanax!
0 -
I have put the deodorant in an old tea tin, also a 4 oz. mason jar. I apply with fingers.
0 -
My hair grew in salt an pepper too. I mean black and gray. I have brown and gray hair not black. Even my eyebrows grew in black but eventually became normal. Here is are my hair growth photos starting from the right (1 week before surgery/5 weeks before first chemo). Dates in the lower left corner linky
0 -
Media Release
Basel, 19 December 2014
Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
- MARIANNE was designed to evaluate three HER2-targeted regimens in previously untreated (first line) advanced HER2-positive breast cancer (Kadcyla alone, Kadcyla plus Perjeta, Herceptin plus chemotherapy)
- Study met non-inferiority endpoint, showing similar progression-free survival (PFS) among the three arms
- Study did not meet PFS superiority endpoint for Kadcyla-containing regimens
- Results do not impact approved uses of Kadcyla or Perjeta in advanced HER2-positive breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens – Kadcyla® (trastuzumab emtansine) plus Perjeta® (pertuzumab), Kadcyla alone, and Herceptin® (trastuzumab) plus taxane chemotherapy – in people with previously untreated (first line) advanced HER2-positive breast cancer. The study showed the three regimens helped people live without their disease worsening (PFS) for a similar amount of time, meeting its non-inferiority endpoint as assessed by an Independent Review Committee (IRC). However, neither Kadcyla-containing treatment arm significantly improved PFS compared to Herceptin and chemotherapy. Adverse events observed in the two experimental arms of the study were generally consistent with those seen in previous studies of Kadcyla and/or Perjeta1.
In their approved uses for advanced HER2-positive breast cancer, Kadcyla and Perjeta have been shown to extend survival. Kadcyla is approved for people with previously treated disease (second and later lines). Perjeta is approved in combination with Herceptin and chemotherapy for people with previously untreated disease (first line).
"Over the past 30 years, we have made significant progress in treating one of the most aggressive forms of advanced breast cancer with medicines that extend patients' lives across the course of their disease. In this study, we had hoped to show improvement in progression-free survival without the use of traditional chemotherapy in the first line treatment of patients with advanced HER2-positive breast cancer," said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global Product Development. "While MARIANNE didn't achieve this result, we will continue to study these medicines, as well as investigational treatments for other types of breast cancer, with the goal of improving outcomes for patients."
Data from the MARIANNE study will be presented at an upcoming medical meeting. Roche will discuss the data with health authorities.
About the MARIANNE Study
The Phase III MARIANNE study (NCT01120184; BO22589) is an international, randomized, multicenter, three-arm study involving 1,095 people with HER2-positive advanced breast cancer – either with inoperable locally advanced disease that had worsened during or returned after previous treatment, or with disease that had spread to other areas of the body.2People with advanced breast cancer at diagnosis and people whose disease had worsened following either neoadjuvant or adjuvant treatment were eligible.
People enrolled in the study received treatment with either:
- A combination of Kadcyla and Perjeta
- Kadcyla alone, or
- Herceptin and either docetaxel or paclitaxel chemotherapy.
The primary endpoint of the MARIANNE study is PFS as assessed by an Independent Review Committee (IRC). Secondary endpoints include overall survival, response rate, and the incidence of adverse events. Differences in these endpoints were assessed in each of the Kadcyla-containing treatment arms compared to the Herceptin plus chemotherapy arm, and also between the two Kadcyla-containing arms.
About Kadcyla
Kadcyla is one of three targeted medicines that Roche has developed for the treatment of HER2-positive breast cancer. It is a type of medicine called an antibody-drug conjugate (ADC), combining two anti-cancer properties: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the cytotoxic chemotherapy agent DM1. In Kadcyla, trastuzumab and DM1 are joined together using a 'stable linker' to deliver DM1 directly to HER2-positive cancer cells. Roche licenses technology for Kadcyla under an agreement with ImmunoGen, Inc.
About Perjeta
Perjeta is a medicine that targets the HER2 receptor, a protein found on the outside of many normal cells and in high quantities on the outside of cancer cells in HER2-positive cancers. Perjeta is designed specifically to prevent the HER2 receptor from pairing (or "dimerizing") with other HER receptors (EGFR/HER1, HER3 and HER4) on the surface of cells, a process that is believed to play a role in tumor growth and survival. Binding of Perjeta to HER2 may also signal the body's immune system to destroy the cancer cells. The mechanisms of action of Perjeta and Herceptin are believed to complement each other, as both bind to the HER2 receptor, but to different places. The combination of Perjeta and Herceptin is thought to provide a more comprehensive blockade of HER signaling pathways, thus preventing tumor cell growth and survival.
About Roche's medicines for HER2-positive breast cancer
Roche has been leading research into the HER2 pathway for over 30 years and is committed to improving the health, quality of life and survival for people with both early and advanced HER2-positive disease.
Roche has developed three innovative medicines that have helped transform the treatment of HER2-positive breast cancer: Herceptin, Perjeta and Kadcyla. HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 20 percent of patients. Over the past 15 years, the outlook for people with HER2-positive disease has improved to the extent that those with this form of the disease treated with these innovative medicines now typically experience better outcomes than people with less aggressive HER2-negative disease.
Eligibility for treatment with Roche's HER2-targeted medicines is determined via a diagnostic test, saving time from the outset by identifying those patients who will likely benefit from these medicines.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
1.Roche data on file.
2.U.S. National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/show/NCT01120184.Downloads
Services
Additional information
- Roche in Oncology
- Follow us via @roche on Twitter and on LinkedIn athttps://www.linkedin.com/company/1602.
Interesting press release today from my company. Looks like Herceptin and Perjeta, without chemo is equal to Herceptin and chemo for disease free survival. Maybe soon the day will come when Her 2+ means no chemo, no hair loss, no nausea, none of what we all went through!
0 -
Interesting press release today from my company (above). Maybe the day will come soon when us Her 2+ girls no longer need systemic chemical chemo, but can just do the biologics (Perjeta and Kadcyla). :-)
Mammo went well today, all is good for another 6 months for me. Whew, those things stress me out!
0 -
Pbrain, thanks for the press release and woohoo! for a clean mammo!
0 -
pbrain happy for a clean mammo.
0 -
Congrats Pbrain - good news.
0 -
Congrats Pbrain. What a relief. Thank you for the news release. I start on TCH with Perjeta Monday. My SNB was negative. They got 4 nodes.
PMR53
0 -
Hi all you triple positive ladies!! I am curious to see who if anyone has had a hysterectomy due to being hormone positive. I am thinking about it and from what I have read it has been beneficial. I am young(39) and want to minimize my risk of reoccurance as much as possible!
Thanks,
Kathy
0 -
PMR53, good luck to you. That protocol worked well for me in anticipation of surgery.
Kathy, I wonder about that too. I know that we produce estrogen in other places too, though (adrenal glands and fat cells), so removing the ovaries doesn't remove all estrogen.
0 -
I am back from a 4 week hiatus, after undergoing a full abdominal Hysterectomy and wanted to thank everyone for all their help and valuable input. Special thanks to SpecialK, your experience and advice was so helpful and encouraging!
I also want to share my story to let others know, that while very rare and shocking, it is possible to fall out of Chemopause, 3 years after treatment, and one month from my 52nd birthday. The experience was at first terrifying because I didn't think it was possible. Even my oncologist was worried that the bleeding might be caused by Endometrial Cancer from the the Tamoxifen. Luckily everything checked out B-9!
Present moment...Wonderful moment.
0 -
Pbrain, congrats on the clean mammo! The best part of the press release is where they said Her2+ BC now has a better outcome than less aggressive Her2- BC.
0 -
I'm new here and appreciate all of the comments and wisdom of those who have walked this road before me. Have learned so much from all of you already.
Just over a month ago I had mx for 6cm grade 3 DCIS and PMX for the other breast. Surgical pathology showed 2 very small areas (2mm and 3mm) of stage 1a grade2 IDC. SNB was 0/1. I'm ER+100/PR+40/HER2+ by FISH, Ki-67 10%. The PMX showed ADH and scattered microcalcs. I am hoping pathology has enough tissue to be retested in order to enter the ATEMPT trial, but my medical oncologist says that unless I qualify for the trial then the only adjuvant therapy for me will be Tamoxifen. Only child but with a strong family history of cancer (mother dx at age 46 with lung and brain and died the week of dx and father died of lung and esophageal at age 73 (dx at age 66). After years of basal/squamous skin cancers in situ, this year brought my first invasive squamous cell skin cancer. I'm probably over reacting, but I feel like a ticking time bomb with the HER2+.
Do any of you have any experiences to share with triple positive very small IDC or have any of you been able to receive treatment other than hormonal for it? Medical oncologist is humoring me by presenting my case to the review board tomorrow but also agrees I have a good possibility of the HER2 resurfacing as a distant met at some point. I am grateful that my IDC was small and node negative, but I feel like I'm in no man's land waiting for the this to possibly progress..
Thanks in advance for any advice you can pass along.
0 -
I was dx'd with a 4 mm triple pos IDC in Sept. Node neg as well. My first MO said what yours did - hormonal therapy only. After hearing what bad actors Her2 tumors can be, I was very scared to not treat that aspect of the tumor. I did a huge amount of research and got three more MO opinions. I also consulted Johns Hopkins via their online service and they strongly suggested getting another opinion from an academic center. I am now in the Atempt trial, though I got the control arm, Taxol/Herceptin. All the MOs except the first one thought it was reasonable to go either route, hormonal Tx only or T/H. The truth is that no one knows what the right approach is for small Her2 pos tumors as they were excluded from all the early Herceptin trials. The few studies that break down by size have very small numbers of small triple pos tumors, but show recurrence rates for T1a (1-5mm) between 3 and 9% without Her2 targeted Tx. Best guess is that Her 2 Tx probably cuts that in half. So at a tumor your size the decision is whether you are willing to take on the SE and risks of chemo for an absolute benefit that is likely somewhere between a 1.5 to 4.5% improvement in outcome. It is a tough call, but it should be yours to make, not the doctor's. These small tumors usually have great outcomes, but they can and do metastasize. I understood I was only getting a small absolute benefit from Tx, but I knew it was the right choice for me. The Atempt trial is a great idea for you if you do decide on more Tx. Both arms are relatively well tolerated though not without risk. You can either plead your case with your current MO or get more opinions. You will surely find one who is willing to refer you or treat you with T/H if your tumor is too small for them to test.
Feel free to PM me if you want to talk more. Best of luck!
0 -
Thanks for the reply, TTfan. I am at a leading academic cancer center and have been spoiled by an all star team of doctors until this point. My med oncologist just completed her fellowship and is just not prepared to venture outside of standard protocol. I have placed a request through patient advocacy for a different doctor but that may take 2 weeks. Maybe I should get second opinions during that time. Thanks again for sharing your story. I'm hoping to join you in the ATEMPT trial as that seems to be the easiest path.
0 -
Yay Pbrain
0 -
Great news Pbrain
0 -
CassieCat-I think you have surgery tomorrow per your signature. If so, positive thoughts your way for a successful surgery and a speedy recovery.
0 -
Yay Pbrain for a clean mammo. What do they do at 6 month rechecks with reconstructed breasts?0 -
Since I have been on leave following my surgery and now have my final pathology results, I have been doing research on the internet, but I haven't found too much info except for one article that this type of cancer impeded the HER2 drugs from reaching the cancer. My final pathology was a mucinous adenocarcinoma which rarely is HER2+. Did anyone have the same histology report?0 -
pbrain - yay for the good mammo! And thanks for posting the study info from Roche.
Bren - love your new pic!
Ella - glad to see you! So glad all went well.
Momtothree - there are a couple of ladies who post here who had small amounts of IDC, as well as a thread I will link for you. Is your MO refusing to treat you with chemo and Herceptin, or just not recommending it? There are some who are using weekly Taxol and Herceptin for IDC less than 5mm also - will link that too along with the study info.
https://community.breastcancer.org/forum/80/topic/...
https://community.breastcancer.org/forum/80/topic/...
http://www.ascopost.com/ViewNews.aspx?nid=10846
0
